Announcing the launch of Breakthroughs Today, Cures Tomorrow, our 20th anniversary campaign!
By Anne-Marie Green, NETRF Director of Digital Communications NETRF brought the NET Impact Thrivership & Research Education Program to Alabama for the first time on
By Anna Greene, PhD, NETRF Director of Research Pancreatic neuroendocrine tumors (PanNETs) are rare and tricky. Some grow slowly and never cause trouble, while others
By Anne-Marie Green, Director of Digital Communications As a 19-year veteran educator, Dr. Barbara Dunham’s learning instincts were set in motion when she was diagnosed
Congress recently passed new tax legislation that will change how charitable contributions are treated starting in 2026. While the bill is complex, we want to
By Anna Greene, PhD, NETRF Director of Research What if small intestine neuroendocrine tumors (SI-NETs), often diagnosed in people over age 60, actually begin decades
By Anna Greene, PhD, NETRF Director of Research An important advancement in neuroendocrine neoplasm (NEN) patient care has been released: the Position Statement on Nutritional
The world’s first clinical trial for CAR T-cell therapy in neuroendocrine tumors has advanced to a higher dose level, an indication of progress. Advancing to
By Anna Greene, PhD, NETRF Director of Research A recent study by Suriya Baskar, MD, and Udhayvir Singh Grewal, MD, published in the Journal of
Perspective Therapeutics has begun enrolling participants into the next phase of its clinical trial of a new targeted alpha radiation therapy for neuroendocrine tumors (NETs).
“Where do you see yourself in five years?” I’ve stopped answering that question. Five years ago I was 31. Five years ago I was planning my wedding. Five